Drug
Azacitidine
Azacitidine: highest development phase Phase 2, developed by Hikma, Incyte, Johnson & Johnson. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Hikma, Incyte, Johnson & Johnson
Trials
| Drug | Phase | Indication |
|---|---|---|
| Azacitidine NCT04264806 | Phase 2 | Myelodysplastic Syndromes |
| Azacitidine NCT02959437 | Phase 1/2 | Solid Tumors |
| Azacitidine NCT06326697 | Phase 1 | Acute Myeloid Leukaemia |
| Azacitidine NCT06572982 | Not Applicable | Acute Myeloid Leukemia |
Latest
No recent events.
Follow Azacitidine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.